Eli Lilly presented early clinical findings for brenipatide, a once-weekly dual GIP/GLP-1 receptor agonist, targeting central nervous system and inflammatory pathways linked to reward, addiction, and neuropsychiatric conditions. At Psych Congress 2026, Lilly shared Phase 1 data from its J2S-MC-GZMD study to support dose selection across substance use, psychiatric, and immunologic indications. Lilly reported a mean half-life range of about 9 to 12.5 days, supporting exposure durability beyond the weekly dosing interval. The company outlined Phase III trial designs aimed at major depressive disorder and alcohol use disorder, building on the clinical and commercial momentum behind tirzepatide (Mounjaro, Zepbound) as a reference point for the modality. The presentation reframes Lilly’s incretin platform toward neuroscience and immune-linked biology, setting up an early pipeline test versus established CNS and addiction development programs.